Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

M-CENK

Cell therapy (NK cells) · Kills target cells, directed at tumor cells · developed by ImmunityBio

Phase 2 Most advanced trial

IBRX Developer

3 Registered trials

What is M-CENK?

M-CENK is an autologous memory cytokine-enriched natural killer cell therapy administered intravenously. It is being studied in metastatic solid tumors, platinum-resistant ovarian cancer, and high-risk prostate cancer, with dosing of 0.15–0.75 × 10⁹ cells per infusion.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (NK cells)
Targets: tumor cells (antigen)
Mechanism: Kills target cells, directed at tumor cells
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 637UW2W2GM

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06765954	Phase 2	High-risk Prostate Cancer	Withdrawn	IBRX
NCT06710288	Phase 2	Platinum-resistant Ovarian Cancer	Recruiting	IBRX
NCT04898543	Phase 1	Metastatic Solid Tumor	Active not recruiting	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Solid TumorPlatinum-resistant Ovarian CancerHigh-risk Prostate Cancer

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind M-CENK

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z